Universal reference book for medicines
Name of the preparation: PHOSPHOGLIV ® (PHOSPHOGLIV)

Active substance: glycyrrhizinic acid, non welcome

Type: Hepatoprotector with immunomodulating and antiviral action

Composition, form of production and packaging
Capsules hard gelatinous, №0, with the case of orange color and a cover of black color; the contents of the capsules are a granular powder from white with a slightly yellowish tinge to a light yellow color, with a weak specific odor.
1 caps.

phospholipids (lipoid C80) (in terms of the main component - phosphatidylcholine 73-79%) 65 mg

sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 35 mg

10 pieces.
- packings cellular planimetric (5) - packs cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2016.


Combined drug.

Has a membrane-stabilizing, hepatoprotective and antiviral effect.

Phosphatidylcholine (the active substance of phospholipids) is the main structural element of cellular and intracellular membranes, capable of restoring their structure and functions in damage, providing a cytoprotective effect.
Normalizes protein and lipid metabolism, prevents the loss of hepatocytes of enzymes and other active substances, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis of the liver.
Glycyrate (glycyrrhizic acid and salts) has an anti-inflammatory effect, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, enhancing phagocytosis, increasing the activity of natural killer cells.
Has a hepatoprotective effect due to antioxidant and membrane-stabilizing activity. Potentiates the effect of endogenous glucocorticosteroids, providing anti-inflammatory and anti-allergic effects in non-infectious liver lesions.
When the skin is damaged due to the membrane-stabilizing and anti-inflammatory effect of the components, it limits the spread of the process and promotes regression of the disease.



More than 90% of the ingested phospholipids are absorbed from the small intestine.
Most are cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with a current of lymph enters the blood, from where, mainly, in the high-density lipoprotein linked to the liver.
Pharmacokinetics in humans was studied with the help of dinolonelephosphatidylcholine with a radioactive label - 3 N (choline part) and 14 C (the residue of linoleic acid).
C max 3 N is reached after 6-24 hours, amounting to 19.9% ​​of the prescribed dose; 14 С - in 4-12 hours, making 27.9%.
T 1/2 of the choline component is 66 hours, the residue of linoleic acid is 32 hours. In feces 2% 3 H and 4.5% - 14 C are detected;
in urine - 6% 3 N and a minimum amount of 14 C.
Both isotopes are absorbed in the intestines by more than 90%.

Glycyrrhizic acid

After ingestion inside the intestine under the influence of the? -glucuronidase enzyme produced by bacteria of normal microflora, an active metabolite of α-glycyrrhetic acid is formed from glycyrrhizic acid, which is absorbed into the systemic blood stream.
In the blood? -glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Isolation of? -glycyrrhic acid occurs predominantly with bile, in the residual amount - with urine.
According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and speed of its absorption by more than 2 times.


- fatty liver degeneration (hepatosis);

- other liver damage (alcoholic, toxic, including medicinal);

- as part of complex therapy of viral hepatitis, liver cirrhosis, and psoriasis.


The drug is taken orally during a meal.
Capsules should be swallowed, not liquid, squeezed with a small amount of liquid.
Adults and children over 12 years of age are prescribed 2 caps.
3 times / day.
Duration of use can be up to 6 months, on average - 3 months.


Typically, the preparation of Phosphogliv ® is well tolerated, side effects develop very rarely, according to the post-registration data, the frequency is <1/10 000.

Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.

From the cardiovascular system: transient (transient) increase in blood pressure, peripheral edema.

From the digestive system: dyspepsia (belching, nausea, bloating), discomfort in the abdomen.

If these symptoms occur, stop taking the medication and consult a doctor.


- antiphospholipid syndrome;

- Pregnancy (data on effectiveness and safety is not enough);

- lactation period (data on efficacy and safety is not enough);

- children's age till 12 years;

- Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug.

With caution should prescribe the drug to patients with portal hypertension, arterial hypertension.
If you have these diseases, consult your doctor before starting the drug.

The drug is contraindicated for use in pregnancy and lactation (data on efficacy and safety is not enough).


Caution should be given to patients with portal hypertension.


Contraindicated in children under the age of 12 years.


In the event of an increase in blood pressure should stop taking the drug and see a doctor.

Impact on the ability to drive vehicles and manage mechanisms

The drug does not adversely affect the ability to drive vehicles and perform other work that requires an increased concentration of attention and speed of psychomotor reactions.


Currently, cases of an overdose of Phosphogliv ® are not registered.


The drug interaction of the preparation Phosphogliv ® is not described.


The drug is approved for use as a means of OTC.


The drug should be stored out of the reach of children at a temperature of no higher than 25 ° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!